Edition:
United Kingdom

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

131.34USD
15 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$131.34
Open
$130.28
Day's High
$133.42
Day's Low
$127.20
Volume
232,907
Avg. Vol
448,026
52-wk High
$176.44
52-wk Low
$46.07

Latest Key Developments (Source: Significant Developments)

Sarepta Announces Clinical Hold Lifted For Its Duchenne Muscular Dystrophy Micro-Dystrophin Gene Therapy Program
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA ANNOUNCES CLINICAL HOLD LIFTED FOR ITS DUCHENNE MUSCULAR DYSTROPHY MICRO-DYSTROPHIN GENE THERAPY PROGRAM.SAREPTA THERAPEUTICS - IN RESPONSE, ACTION PLAN DEVELOPED, SUBMITTED TO FDA, INCLUDING AUDIT OF PLASMID SUPPLIER.SAREPTA THERAPEUTICS - PLAN SUBMITTED TO FDA, INCLUDES COMMITMENT TO USE GMP-S PLASMID FOR ALL FUTURE PRODUCTION LOTS.SAREPTA THERAPEUTICS INC - CO HOPES TO REGISTER FOR TRIAL FOR MICRO-DYSTROPHIN PROGRAM & COMMENCING TRIAL BY YEAR-END 2018.  Full Article

Sarepta Receives Negative CHMP Re-Examination Opinion For Eteplirsen
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA RECEIVES NEGATIVE CHMP RE-EXAMINATION OPINION FOR ETEPLIRSEN.SAREPTA THERAPEUTICS INC - WILL SEEK FURTHER SCIENTIFIC ADVICE FROM EUROPEAN MEDICINES AGENCY ON A POSSIBLE PATH TO BRING ETEPLIRSEN TO PATIENTS IN EUROPE.SAREPTA -WILL SEEK FURTHER SCIENTIFIC ADVICE FROM EUROPEAN MEDICINES AGENCY ON A POSSIBLE PATH TO BRING ETEPLIRSEN TO PATIENTS IN EUROPE.SAREPTA THERAPEUTICS INC - EXPECTS EUROPEAN COMMISSION (EC) TO ADOPT CHMP OPINION BY YEAR-END 2018.  Full Article

Sarepta Therapeutics Q2 Non-GAAP Loss Per Share $0.43
Wednesday, 8 Aug 2018 

Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q2 NON-GAAP LOSS PER SHARE $0.43.Q2 REVENUE $73.5 MILLION VERSUS I/B/E/S VIEW $71.6 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.89 -- THOMSON REUTERS I/B/E/S.ON A NON-GAAP BASIS, NET LOSS FOR Q2 WAS $0.43 PER SHARE.QTRLY GAAP NET LOSS PER SHARE $1.67.  Full Article

Sarepta Receives Negative CHMP Opinion For Exondys
Friday, 1 Jun 2018 

June 1 (Reuters) - Sarepta Therapeutics Inc ::AS ANTICIPATED, SAREPTA RECEIVES NEGATIVE CHMP OPINION FOR EXONDYS® (ETEPLIRSEN) TO TREAT PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY IN EUROPE.SAREPTA THERAPEUTICS INC - SAREPTA WILL SEEK RE-EXAMINATION OF OPINION AND REQUEST THAT A SCIENTIFIC ADVISORY GROUP (SAG) BE CONVENED.SAREPTA THERAPEUTICS INC - WILL SEEK RE-EXAMINATION OF OPINION AND REQUEST THAT A SCIENTIFIC ADVISORY GROUP (SAG) BE CONVENED.SAREPTA THERAPEUTICS INC - RE-EXAMINATION PROCESS IS EXPECTED TO BE COMPLETED BY YEAR-END 2018.SAREPTA THERAPEUTICS INC - WILL ALSO REQUEST A SCIENTIFIC ADVISORY GROUP ON DMD BE CALLED.SAREPTA THERAPEUTICS INC - WILL REQUEST A RE-EXAMINATION OF OPINION, WHICH WILL RESULT IN ASSIGNMENT OF A NEW RAPPORTEUR AND CO-RAPPORTEUR.  Full Article

Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH.Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION.SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION.SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION.SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​.  Full Article

Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Sarepta Therapeutics Inc ::CAPITAL VENTURES INTERNATIONAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN SAREPTA THERAPEUTICS INC AS OF DECEMBER 11, 2017 - SEC FILING.  Full Article

Sarepta Therapeutics prices $475 million of convertible senior notes due 2024
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics prices $475 million of convertible senior notes due 2024.Sarepta Therapeutics-‍priced $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024​.Sarepta Therapeutics - ‍notes will bear cash interest at a rate of 1.50%, payable on May 15 and November 15 of each year, beginning on May 15, 2018​.  Full Article

Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024.Sarepta Therapeutics Inc - ‍Chief Executive Officer indicates interest in purchasing $2 million of shares of Sarepta's common stock​.Sarepta - ‍intends to use a portion of net proceeds from offering to pay cost of certain capped call transactions​.Sarepta - ‍purchase price/share of stock bought by ingram expected to equal closing price/share of co's stock on date of pricing of offering​.  Full Article

Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051.Sarepta Therapeutics Inc - will immediately initiate its phase 1/2a clinical trial and begin screening patients with dmd amenable to skipping exon 51​.  Full Article

Sarepta Therapeutics says FDA clears gene therapy IND application
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Sarepta Therapeutics Inc -:Sarepta Therapeutics and Nationwide Children’S Hospital announce U.S. Food And Drug Administration (FDA) clearance of the IND application for the GALGT2 gene therapy program.Sarepta Therapeutics- ‍IND application for GALGT2 gene therapy program was cleared by FDA​.Sarepta Therapeutics - Nationwide Children's is on track to initiate Phase 1/2A clinical trial in individuals with DMD by year-end 2017 ​.  Full Article

UPDATE 2-Summit plunges 80 pct after muscle-wasting disorder drug fails

* Plummets 80 pct to touch record low (Adds details on trial, analyst comment)